U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07236151) titled 'Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT' on Sept. 26.
Brief Summary: The goal of this clinical trial is to learn if sequential CD19/CD22 CAR-T cell therapy following autologous stem cell transplantation (ASCT) works to treat relapsed or refractory large B-cell lymphoma (LBCL) in adults. It will also learn about the safety of this treatment combination. The main questions it aims to answer are:
Does ASCT followed by sequential CD19/CD22 CAR-T therapy improve complete response rates in participants with relapsed/refractory LBCL? What medical problems do participants have when receiving this treatment combination? Resea...